Nanoform Finland Oyj logo

Nanoform Finland Oyj (NANOFH)

Market Open
9 Dec, 10:33
XHEL XHEL
0. 96
+0.01
+0.95%
207.88M Market Cap
- P/E Ratio
0% Div Yield
38,801 Volume
-0.27 Eps
0.95
Previous Close
Day Range
0.94 0.97
Year Range
0.72 1.6
Want to track NANOFH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 79 days

Summary

NANOFH trading today higher at €0.96, an increase of 0.95% from yesterday's close, completing a monthly increase of 2.35% or €0.02. Over the past 12 months, NANOFH stock lost -31.5%.
NANOFH is not paying dividends to its shareholders.
The last earnings report, released on Nov 20, 2025, exceeded the consensus estimates by 0.06%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports. The next scheduled earnings report is due on Feb 26, 2026.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XHEL (EUR).

NANOFH Chart

Similar

Modulight Oy
1.15
0%

Nanoform Finland Oyj (NANOFH) FAQ

What is the stock price today?

The current price is €0.96.

On which exchange is it traded?

Nanoform Finland Oyj is listed on XHEL.

What is its stock symbol?

The ticker symbol is NANOFH.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 207.88M.

When is the next earnings date?

The next earnings report will release on Feb 26, 2026.

Has Nanoform Finland Oyj ever had a stock split?

No, there has never been a stock split.

Nanoform Finland Oyj Profile

Biotechnology Industry
Healthcare Sector
Mr. Albert Alexander Haeggstrom CEO
XHEL Exchange
FI4000330972 ISIN
FI Country
165 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Nanoform Finland Oyj is a trailblazer in the field of nanotechnology and drug particle engineering, catering to the pharmaceutical and biotech sectors across Europe and the United States. Since its inception in 2008, the company has been dedicated to revolutionizing the way active pharmaceutical ingredients (APIs) are developed and produced. Headquartered in Helsinki, Finland, Nanoform aims to enhance the efficacy and performance of drugs by leveraging its cutting-edge proprietary technology. The company’s innovative approach to nanoparticle production not only increases the bioavailability of drugs but also opens up new possibilities for drug development and delivery.

Products and Services

  • Nanoparticle Production Services
  • Utilizing its proprietary Controlled Expansion of Supercritical Solutions (CESS) technology, Nanoform provides unique nanoparticle production services. This advanced method allows for the precise engineering of drug particles to nanoscale dimensions, resulting in enhanced solubility and bioavailability. This innovative service is tailored to meet the specific needs of clients, aiming to improve the performance and efficacy of their pharmaceutical products.

  • STARMAP
  • STARMAP is a cutting-edge, secure online portal offered by Nanoform that enables the performance of a large number of in-silico CESS experiments. This platform allows clients to simulate the nanoparticle engineering process, providing insightful data and predictions on how to optimize drug formulations for better outcomes. STARMAP serves as a powerful tool for accelerating drug development cycles and achieving more predictable and effective results.

Contact Information

Address: Cultivator II, Helsinki, Finland, 00790
Phone: 358 2937 00150